On December 16, 2024 Microbio Co., Ltd. (4128) reported encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage IIIb/IV non-small cell lung cancer (NSCLC) (Press release, Microbio Co, DEC 16, 2024, View Source [SID1234649143]). The trial showed a threefold increase in the objective response rate (ORR) for the MS-20-Keytruda group (75%) compared to Keytruda alone (25%). Additionally, the median progression-free survival (PFS) for MS-20 patients improved from 4.5 months to over 12 months, with a complete response (CR) rate of 12.5%.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Enhancing Immunotherapy with MS-20
MS-20, developed by Microbio, is a microbiome-based postbiotic designed to improve cancer immunotherapy by modulating the gut microbiome. "The results support MS-20’s potential to reshape the microbiome and enhance Keytruda’s effectiveness in treating advanced NSCLC," said Dr. Wan-Jiun Chen, Executive VP of Research & Development at Microbio. "Currently, hundreds of ongoing trials are aimed to find novel therapeutic agents for improving the efficacy of cancer immunotherapy, and this proof-of-concept trial supports the use of MS-20 in such application."
This randomized, double-blind, placebo-controlled trial involved 15 patients, with 12 analyzed in the modified intent-to-treat (mITT) population (ClinicalTrials.gov ID: NCT04909034). Of the 8 patients receiving MS-20 and Keytruda, 6 (75% ORR) responded positively, including 1 with an ongoing CR lasting over 22 months and 5 with partial responses (PR). In contrast, only 1 of 4 patients in the placebo and Keytruda group showed a PR (25% ORR). The median PFS for the MS-20-Keytruda group was over 12 months, compared to 4.5 months in the placebo group.
Scientific Insights and Next Steps
Preclinical research published in Gut Microbes earlier this year supported these findings, showing that MS-20 enhances immune responses by increasing effector CD8 T cells in the tumor microenvironment. Microbio plans to use these results to pursue global collaborations and further its microbiome-based cancer immunotherapy platform.